Cliical Trials: Special Interest AEs & AESIs

Training Investigators and Sites to Execute Special Interest AEs & AESIs Reliably Training Investigators and Sites to Execute Special Interest AEs & AESIs Reliably In the realm of clinical trials, especially in oncology clinical research, understanding and addressing adverse events (AEs) and special interest adverse events of special interests (AESIs) is crucial for maintaining the…

Read More “Training Investigators and Sites to Execute Special Interest AEs & AESIs Reliably” »

Vendor and Partner Oversight Considerations in Special Interest AEs & AESIs Vendor and Partner Oversight Considerations in Special Interest AEs & AESIs In the clinical research landscape, the management of Adverse Events (AEs) and Serious Adverse Events (SAEs) is crucial to ensuring patient safety and data integrity. As clinical trials become increasingly complex, particularly in…

Read More “Vendor and Partner Oversight Considerations in Special Interest AEs & AESIs” »

Integrating Special Interest AEs & AESIs With DSURs, PBRERs and Risk Management Plans In the realm of clinical research, ensuring the safety and efficacy of investigational drugs is paramount. Within this framework, the monitoring of adverse events (AEs) and serious adverse events (SAEs) holds critical importance. This article focuses on the integration of Special Interest…

Read More “Integrating Special Interest AEs & AESIs With DSURs, PBRERs and Risk Management Plans” »

Future Trends: AI, Automation and Real-World Data in Special Interest AEs & AESIs Future Trends: AI, Automation and Real-World Data in Special Interest AEs & AESIs As the landscape of clinical trials evolves, the management of adverse events (AEs) and adverse events of special interest (AESIs) becomes increasingly vital. This tutorial explores the future trends…

Read More “Future Trends: AI, Automation and Real-World Data in Special Interest AEs & AESIs” »

Global Considerations for Special Interest AEs & AESIs Across US, EU and UK Programs The acknowledgment and management of Adverse Events (AEs) and Adverse Events of Special Interest (AESIs) are critical components in the conduct of clinical trials. Given the rise in regulatory scrutiny and the increasing complexity of clinical trial landscapes, professionals engaged in…

Read More “Global Considerations for Special Interest AEs & AESIs Across US, EU and UK Programs” »

Global Considerations for Special Interest AEs & AESIs Across US, EU and UK Programs Global Considerations for Special Interest AEs & AESIs Across US, EU and UK Programs Introduction to Special Interest AEs & AESIs In the context of clinical trials, understanding adverse events (AEs) and special interest adverse events of special interest (AESIs) is…

Read More “Global Considerations for Special Interest AEs & AESIs Across US, EU and UK Programs” »

Data Quality and Reconciliation Controls for Robust Special Interest AEs & AESIs Data Quality and Reconciliation Controls for Robust Special Interest AEs & AESIs The management of special interest adverse events (AEs) and adverse events of special interest (AESIs) is critical in oncology clinical research. Enhanced data quality and management protocols have become pivotal for…

Read More “Data Quality and Reconciliation Controls for Robust Special Interest AEs & AESIs” »

Data Quality and Reconciliation Controls for Robust Special Interest AEs & AESIs Introduction to Special Interest Adverse Events (AEs) and Adverse Events of Special Interest (AESIs) In the realm of oncology clinical research, ensuring data integrity and accurate reporting of adverse events (AEs) is of paramount importance. Special interest AEs (typically those with a significant…

Read More “Data Quality and Reconciliation Controls for Robust Special Interest AEs & AESIs” »